SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals gains as its arm set to acquire Utility Therapeutics

03 Jul 2025 Evaluate

Alembic Pharmaceuticals is currently trading at Rs 1000.60, up by 10.95 points or 1.11% from its previous closing of Rs 989.65 on the BSE.

The scrip opened at Rs 999.05 and has touched a high and low of Rs 1010.00 and Rs 980.00 respectively. So far 20842 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 1296.15 on 09-Oct-2024 and a 52-week low of Rs 725.60 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs 1107.80 and Rs 963.75 respectively. The current market cap of the company is Rs 19539.36 crore.

The promoters holding in the company stood at 69.67%, while Institutions and Non-Institutions held 20.37% and 9.96% respectively.

Alembic Pharmaceuticals’ wholly owned subsidiary -- Alembic Pharmaceuticals Inc is all set to acquire Utility Therapeutics (Utility). The objective behind the acquisition is to market the USFDA approved product and underdevelopment product owned by the Utility in USA. The transaction is expected to complete within 30 days. The cost of acquisition is around $12 million in staggered manner over period of time, depending on milestones achieved.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

776.50 -8.45 (-1.08%)
20-Apr-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1238.10
Cipla 1239.20
Zydus Lifesciences 942.70
Lupin 2325.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×